Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose
|
|
- Godfrey Lyons
- 5 years ago
- Views:
Transcription
1 Blackwell Science, LtdOxford, UKBJCPBritish Journal of Clinical Pharmacology36-525Blackwell Science, 2254Original ArticleEntacapone increases concentrations of L-dopaH. Heikkinen et al. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose Helena Heikkinen, Anu Varhe, Tarmo Laine, Jaakko Puttonen, 2 Marjo Kela, 2 Seppo Kaakkola 3 & Kari Reinikainen Orion Corporation, ORION PHARMA, Research Center, Espoo, 2 Orion Corporation, ORION PHARMA, Kuopio and 3 Helsinki University Central Hospital, Department of Neurology, Helsinki, Finland Aims Entacapone is a peripherally acting catechol-o-methyltransferase (COMT) inhibitor. To improve the benefits of oral L-dopa in the treatment of Parkinson s disease (PD), entacapone is administered as a 2 mg dose with each daily dose of L-dopa. This study evaluated the effects of entacapone 2 mg on the pharmacokinetics and metabolism of L-dopa given as standard release L-dopa/carbidopa. Methods Six different doses of L-dopa/carbidopa were investigated in this placebocontrolled, double-blind (regarding entacapone), randomized, single-dose study in 46 young healthy males. The subjects were divided into three groups (n = 4 6). Two different L-dopa/carbidopa doses were administered to each subject (5/ 2.5 mg and 5/37.5 mg, or / mg and /25 mg, or 2/5 mg and 25/ 25 mg). Each dose was given on two occasions; simultaneously with entacapone or with placebo, in random order, on two consecutive study visits, separated by a washout period of at least 3 weeks (four-way crossover design). Serial blood samples were drawn before dosing and up to 24 h after the dose and pharmacokinetic parameters of L-dopa, its metabolites, carbidopa, and entacapone were determined. Results Entacapone increased the AUC(,2 h) of L-dopa to a similar extent at all doses of L-dopa/carbidopa, that is by about 3 4% compared with placebo (P <., 95% CI.5,.4). When evaluated as the ratio of geometric means, entacapone slightly decreased the mean C max values for L-dopa at all L-dopa/ carbidopa doses compared with placebo. When given with entacapone, higher plasma concentrations of L-dopa were maintained for a longer period at all doses of L-dopa/carbidopa. Entacapone also decreased the peripheral formation of 3-Omethyldopa (3-OMD) to about 55 6% of the placebo treatment level (P <., 95% CI -.72, -.35) and increased the mean AUC(,2 h) of 3,4-dihydroxyphenylacetic acid (DOPAC) fold compared with placebo (P <., 95% CI.6,.). The mean AUC(,2 h) of 3-methoxy-4-hydroxy-phenylacetic acid (HVA) following entacapone was approximately 65 75% of that observed with placebo (P <..5, 95% CI.76, -.) at each L-dopa/carbidopa dose except the 5/2.5 mg dose (P >.5, 95% CI.59,.5). The metabolic ratios (MR, AUC metabolite/auc L-dopa) also confirmed that entacapone significantly decreased the proportion of 3-OMD (P <., 95% CI -.85, -.68) and HVA (P <., 95% CI -., -.8) in plasma at each L-dopa/carbidopa dose, whereas the AUC DOPAC/AUC L-dopa ratio was increased again at all doses (P <., 95% CI.26,.9). Entacapone did not significantly affect the pharmacokinetics of carbidopa at any of the doses, nor did L-dopa/carbidopa affect the pharmacokinetics of entacapone. Correspondence: Helena Heikkinen, Research Centre, Orion Corporation ORION PHARMA, Orionintie, PO Box 65, FIN-2 Espoo, Finland. Tel.: ; Fax: ; helena.heikkinen@orionpharma.com Received 24 January 22, accepted 2 July Blackwell Science Ltd Br J Clin Pharmacol, 54,
2 H. Heikkinen et al. Conclusions The 2 mg dose of entacapone similarly and significantly increases the AUC of L-dopa by changing the metabolic balance of L-dopa independent of the L-dopa/carbidopa dose and therefore entacapone is likely to have a similar L-dopa potentiating effect independent of L-dopa dose. Keywords: 3-OMD, carbidopa, DOPAC, entacapone, HVA, L-dopa, pharmacokinetics Introduction Current treatment of Parkinson s disease (PD) involves inhibiting peripheral decarboxylation of oral L-dopa by coadministering a dopa decarboxylase inhibitor (DDC inhibitor) in a fixed combination with L-dopa. With a DDC inhibitor, the decarboxylation of L-dopa decreases and the metabolism shifts to the catechol-o-methyltransferase (COMT) pathway. Consequently, concentration of the product 3-O-methyldopa (3-OMD) increases in peripheral tissues and the degradation to 3-OMD becomes the main metabolic pathway when L-dopa is coadministered with a DDC inhibitor [ 3]. Entacapone is a specific, potent and reversible COMT inhibitor, with an apparent half-life of elimination of h after oral administration and.4 h after i.v. administration [4, 5]. As well as inhibiting the peripheral formation of 3-OMD, entacapone also affects the formation of the other metabolites of L-dopa, including that of 3,4-dihydroxyphenylacetic acid (DOPAC) and 3- methoxy-4-hydroxy-phenylacetic acid (HVA) [6]. The short half-life of elimination and the reversible nature of COMT inhibition enables the safe coadministration of entacapone with each daily dose of L-dopa to increase the benefits of L-dopa therapy for PD [7 ]. It has been shown in earlier single dose studies in healthy volunteers that simultaneous administration of entacapone with L-dopa/carbidopa increases the AUC of L-dopa in a dose-dependent fashion by decreasing its peripheral metabolism [4]. It has been shown in PD patients that entacapone 2 mg significantly increases the availability of L-dopa in plasma when coadministered with varying doses of L-dopa and DDC inhibitor [7, 8, 3]. However, it has not been investigated whether the effects of this dose of entacapone on L-dopa pharmacokinetics and metabolism are dependent on the dose of L-dopa or DDC inhibitor. Standard-release tablets of L-dopa and carbidopa in fixed-dose combinations of / mg, 25/25 mg, 5/2.5 mg, and /25 mg are marketed for treatment of PD. In addition to these standard-release tablets, we included the higher 5/37.5 mg and 2/5 mg doses, also used in clinical practice, in the study design, and investigated the effects of entacapone 2 mg on the pharmacokinetics and metabolism of L-dopa over this range of doses. The pharmacokinetics of carbidopa and entacapone were also determined. Methods Subjects Forty-six Caucasian male volunteers with mean age (± s.d.) of 24 ± 3.4 years (range 8 35 years) and weighing 75 ± 6.8 kg (range kg) with body mass index of 23 ±.6 kg cm -2 (range 9 26 kg cm -2 ) were recruited. The subjects were healthy based on medical history, physical examination, ECG, and clinical laboratory tests and the absence of regular medication. The study protocol, the subject information text, and the consent form were approved by the Ethics Committee of the study centre. The purpose and the course of the study were explained to the subjects and written informed consent was obtained before inclusion in the study. Good Clinical Practice (GCP) Guidelines of the European Community and the Recommendations for Biomedical Research Involving Humans (Declaration of Helsinki of the World Medical Assembly and its amendments) were followed. One subject withdrew from the study for personal reasons. Study design This was a placebo-controlled, randomized, single-dose, four-way cross-over study that was double-blinded for entacapone and open for L-dopa/carbidopa. In addition to the four 24 h study visits, separated by a washout period of at least 3 weeks, the protocol included a screening visit and a poststudy visit. The subjects were divided into three groups of equal size (n = 4 6) in the order that they were enrolled in the study. Each subject was dosed with two different L-dopa/carbidopa doses (5/2.5 mg and 5/37.5 mg, or / mg and / 25 mg, or 2/5 mg and 25/25 mg). All doses consisted of standard-release L-dopa/carbidopa tablets as prescribed to PD patients (5/2.5 mg, /25 mg, / mg, and 25/25 mg). Each of the L-dopa/carbidopa doses were given on two consecutive visits at the same time as either entacapone (2 mg tablet, Orion Pharma, Blackwell Science Ltd Br J Clin Pharmacol, 54,
3 Entacapone increases concentrations of L-dopa Finland) or placebo, which was identical in appearance to the entacapone tablet, and in random order. The drugs were administered orally in the morning after an overnight fast of h during which only tap water was ingested. Tap water was not allowed for the hour prior to dosing of medication, which was given with 2 ml of water. Subjects remained ambulant, fasted and drank no liquids until lunch 4 h after dosing. Assessments Tolerability Adverse events were assessed by spontaneous reporting, inquiry and observation throughout the study. In addition, a physical examination was performed and blood pressure, heart rate and ECG were recorded and clinical laboratory parameters were measured at screening and post study visits. Adverse events were tabulated in system organ classes according to the WHO adverse event dictionary. The frequency, severity and causality to study treatment were evaluated descriptively. Clinical laboratory values were evaluated descriptively and paying special attention to values outside the reference range provided by the analysing laboratory. ECGs, blood pressure and heart rate were also evaluated descriptively. Blood sampling and drug analysis Serial blood samples of ml were collected via a catheter inserted into a forearm vein and transferred to tubes containing ethylenediaminetetraacetic acid. The samples were drawn before dosing and 5, 3, 45, 6, and 9 min and 2, 3, 4, 5, 6, 8,, 2, and 24 h after ingestion of study medication. The samples were kept on ice and plasma was separated by centrifugation at + 4 C, deepfrozen within.5 h of blood collection and stored at -7 C until analysis. An antioxidant, sodium metabisulfite, was added to the plasma samples for the determination of L-dopa, its metabolites and carbidopa before deep-freezing the samples. Plasma concentrations of these analytes were determined by ion-pair, reversed-phase high-performance liquid chromatography (RP-h.p.l.c.) with coulometric detection using a slightly modified previously published method [4]. The plasma used for the determination of entacapone was protected from light during the handling and storing procedures to avoid degradation of the analyte. Plasma concentrations of entacapone were determined by an RP-h.p.l.c. method with amperometric detection. The method was modified from the one published by Karlsson & Wikberg [5]. The limit of quantification was ng ml - for entacapone and 2 ng ml - for the other analytes. The intraassay coefficients of variation (CV) were lower than 5% and the interassay CVs lower than 9% for all the analytes at all concentrations. Evaluation Pharmacokinetics Standard noncompartmental methods were used to determine the pharmacokinetic parameters for L-dopa, 3- OMD, DOPAC, HVA, carbidopa, and entacapone based on the plasma concentration-time data. The maximum plasma concentration (C max ) and the time to maximum plasma concentration (t max ) were recorded directly from observed individual plasma concentrations. The area under the plasma concentration time-curve (AUC) was calculated by conventional linear-trapezoidal summation to time and extrapolation to infinity. The AUC for L- dopa was determined both from time 2 h and to infinity. As L-dopa concentrations were close to zero at 2 h after dosing at all six doses in most subjects, only the AUC(,2 h) is presented. The AUC(, ) was similar to AUC(,2 h). The AUC for 3-OMD was determined from 24 h, and for DOPAC, HVA, carbidopa and entacapone from 2 h for the same reasons as given for L-dopa. Statistical analysis The pharmacokinetic parameters for L-dopa, 3-OMD, DOPAC, HVA, carbidopa and entacapone were summarized using descriptive statistics. Metabolic ratios (MRs) were derived for each subject by dividing the AUC values of 3-OMD, HVA, and DOPAC by that of L-dopa. In addition, the ratio AUC HVA/AUC DOPAC was calculated. An analysis of variance (ANOVA) model appropriate for statistical analysis of cross-over designs was applied to AUC and C max values to test the differences between placebo and entacapone periods for each L-dopa/carbidopa dose. All values were log-transformed prior to analysis, which included sequence, period and treatment as fixed factors, and subject (sequence) and residual error as random effects. The model was applied for each of the three subject groups separately. Wilcoxon signed rank test was used to evaluate the differences in t max values between the entacapone and placebo periods for each L-dopa/ carbidopa dose. In all statistical evaluations, significance was concluded if the 95% confidence interval (95% CI) excluded. In addition, to describe further the effect of entacapone on the AUC and C max of L-dopa and its metabolites, the ratio of geometric means (entacapone vs placebo) with 95% CI was established for each of these parameters. Results Pharmacokinetics of L-dopa The pharmacokinetic parameters for L-dopa after six different doses of L-dopa/carbidopa taken with placebo or 22 Blackwell Science Ltd Br J Clin Pharmacol, 54,
4 H. Heikkinen et al. Table Pharmacokinetic parameters of L-dopa after administering of placebo or entacapone 2 mg with different doses of L-dopa/carbidopa. C max (mg ml - ) t max (h) AUC(,2 h)(mg ml - h) L-dopa/carbidopa dose (mg) Placebo Entacapone Placebo Entacapone Placebo Entacapone 5/ ± ±.2*.59 ±.4.94 ±.5.59 ±.2.76 ±.2 (-.4, -.2) (.5,.33) /.83 ±.26.7 ±.2.75 ± ±.56.2 ± ±.32 (-.29,.7) (.6,.35) /25.85 ±.3.72 ± ±.25.6 ±.59**.43 ± ±.35 (-.34,.2) (.2,.38) 5/ ±.66.9 ±.3**.58 ±.4.9 ± ± ±.8 (-.5, -.) (.5,.34) 2/5.32 ±.24.6 ±.2.79 ±.63.6 ±.68* 3.2 ± ±.72 (-.28,.4) (.24,.4) 25/25.76 ±.69.3 ±.23**.2 ± ±.58* 3.68 ± ±.94 (-.4, -.8) (.22,.38) Values are means with s.d.; 95% confidence intervals on the differences between the mean values for entacapone vs placebo are given in parentheses, n = 4 6. *P <.5, **P <., P <., ANOVA. Statistical significance was concluded if the 95% confidence interval excluded. entacapone are summarized in Table. L-dopa plasma concentration-time profiles are presented in Figure and the mean AUCs for L-dopa, 3-OMD, DOPAC, and HVA in Figure 2. Figure 3 shows the AUC and C max values of L-dopa and its metabolites as geometric mean ratios (entacapone vs placebo) with 95% CI. Entacapone increased the mean AUC(,2 h) of L-dopa by 3 4% with all six L-dopa/carbidopa doses (P <.). There was a decrease in the C max values of L-dopa (Figure 3), but this only attained statistical significance at three of the doses (Table ). Two or more peaks in the plasma concentration-time profile following single dose are frequently observed with L-dopa [, 2, 6, 7]. We also observed this phenomenon, which occurred with and without entacapone and was present at all doses, but especially at the two highest doses of L-dopa. At some doses (/25 mg, 2/5 mg and 25/25 mg) the time to peak concentration of L-dopa was significantly delayed by entacapone (Table ). However, at all doses, with or without entacapone, the initial phase of L-dopa absorption was rapid (Figure ). When given with entacapone, higher plasma concentrations of L-dopa were maintained for a longer period compared with placebo. Pharmacokinetics of 3-OMD, DOPAC and HVA Entacapone decreased the mean AUC(,24 h) of 3-OMD to 55 6% of that observed with placebo, a difference that was statistically significant at all L-dopa/carbidopa doses (P <., 95% CI -.72, -.35) (Figures 2 and 3). The plasma concentrations of DOPAC increased with all six L-dopa/carbidopa doses by fold following entacapone compared with placebo (P <., 95% CI.6,.) (Figures 2 and 3). Similarly, the AUC of HVA decreased following entacapone to 65 75% of the placebo treatment values (P <..5, 95% CI -.76, -.), except after the smallest dose of L-dopa, where the difference did not reach statistical significance (P >.5, 95% CI -. 59,.5) (Figures 2 and 3). Entacapone decreased the ratios of AUC 3-OMD/ AUC L-dopa (P <., 95% CI.85,.68), AUC HVA/AUC L-dopa (P <., 95% CI -., -.8) and it increased the ratio AUC DOPAC/AUC L-dopa (P <., 95% CI.26,.9). A significant decrease was also observed in the ratio of AUC HVA/AUC DOPAC (P <., -.68, -.84). Figure 4 displays the mean plasma concentration-time curves for 3-OMD, DOPAC, and HVA after administration of L-dopa/carbidopa 2/5 mg either with placebo or with entacapone 2 mg, which are representative of the other profiles. Pharmacokinetics of carbidopa and entacapone Table 2 summarizes the pharmacokinetic parameters of carbidopa during the placebo and entacapone phases. The latter did not statistically significantly affect the plasma concentrations of carbidopa at any of the L-dopa/ carbidopa doses. The pharmacokinetics of carbidopa showed considerable interindividual variation (Table 2). The pharmacokinetic parameters for entacapone are summarized in Table 3. The mean C max of entacapone was about. mg ml - at most of the L-dopa/carbidopa doses, although it was slightly lower at the two highest doses. The peak concentration of entacapone was reached at.8 to.2 h at the lower doses of L-dopa, increasing to.5 and.8 h at the two highest doses Blackwell Science Ltd Br J Clin Pharmacol, 54,
5 Entacapone increases concentrations of L-dopa.5 5/2.5 mg.8 / mg Placebo Entacapone /25 mg.4 5/37.5 mg Plasma L-dopa (mg ml ) /5 mg.8 25/25 mg Figure Plasma concentration profiles of L-dopa after administration of placebo or entacapone (2 mg) with six different doses of L-dopa/carbidopa. Data are presented as means with s.e. mean, n = 4 6. Time (h) Tolerability Adverse events reported following the different doses of L-dopa/carbidopa with and without entacapone were similar. Headache and nausea were the most common ones, in addition to respiratory disorders observed mainly during the post-study period. Nausea was more common with the high doses of L-dopa. Almost all the adverse events reported were mild or moderate. One serious adverse event was reported, but this was later assessed as unrelated to the study drug. Discussion Entacapone 2 mg increased the mean AUC of L-dopa significantly and consistently by 3 4% when it was given with six different doses of L-dopa/carbidopa. The increase in the amount of carbidopa from mg to 22 Blackwell Science Ltd Br J Clin Pharmacol, 54,
6 H. Heikkinen et al. 7 L-dopa 8 3-OMD 6 5 Placebo Entacapone AUC (,2 h)(mg ml h) /2.5 / /25 5/37.5 2/5 25/25 DOPAC /2.5 / /25 5/37.5 2/5 25/25 HVA * NS ** * 5/2.5 / /25 5/37.5 2/5 25/25 5/2.5 / /25 5/37.5 2/5 25/25 L-dopa/carbidopa dose (mg) Figure 2 Mean AUCs of L-dopa and its metabolites after six different doses of L-dopa/carbidopa administered concomitantly with placebo or entacapone (2 mg). Data are presented as means with s.e. mean, n = 4 6. ANOVA P <., **P <., *P <.5, NS not significant. Table 2 Pharmacokinetic parameters of carbidopa after administering of placebo or entacapone 2 mg with different doses of L-dopa/carbidopa. L-dopa/carbidopa dose (mg) C max (ng ml - ) t max (h) AUC(,2h) (ng ml - h) Placebo Entacapone Placebo Entacapone Placebo Entacapone 5/ ± 23 4 ± 9.9 ±. 2. ±.7 32 ± 92 2 ± 76 (-.22,.93) (-.37,.6) / 3 ± 8 33 ± ±.9 2. ±.6 95 ± 7 93 ± 66 (-.8,.9) (-.56,.97) /25 82 ± ± ± ± ± ± 6 (-.63, 46) (-.87,.67) 5/ ± 4 ± ± ± ± 7 55 ± 226 (-.63,.56) (-.7,.88) 2/5 26 ± ± ±. 2.9 ± ± ± 93 (-.4,.47) (-.49,.72) 25/25 54 ± ± ± ±. 229 ± 8 32 ± 5 (-.3,.85) (-.,.) Values are means with s.d., n = 4 6; 95% confidence intervals on the differences between the mean values for entacapone vs placebo are given in parentheses. There were no statistically significant differences between entacapone and placebo. Statistical significance was concluded if the 95% confidence interval excluded Blackwell Science Ltd Br J Clin Pharmacol, 54,
7 Entacapone increases concentrations of L-dopa L-dopa 3-OMD.6 AUC C max.6 AUC C max Cl 95%.8.6 Cl 95% /2.5 / /25 5/37.5 2/5 25/25 5/2.5 / /25 5/37.5 2/5 25/25 5/2.5 / /25 5/37.5 2/5 25/25 5/2.5 / /25 5/37.5 2/5 25/25 L-dopa/carbidopa (mg) DOPAC HVA 3 AUC C max.6 AUC C max Cl 95%.5.5 Cl 95% /2.5 / /25 5/37.5 2/5 25/25 5/2.5 / /25 5/37.5 2/5 25/25 5/2.5 / /25 5/37.5 2/5 25/25 5/2.5 / /25 5/37.5 2/5 25/25 L-dopa/carbidopa (mg) Figure 3 AUC and C max values for L-dopa, 3-OMD, HVA and DOPAC; the ratio of geometric means with 95% confidence interval (CI 95% ) after administration of six different doses of L-dopa/carbidopa concomitantly with entacapone 2 mg vs. the administration of the same L-dopa/carbidopa dose with placebo. Table 3 Pharmacokinetic parameters for entacapone (2 mg) after administration with different doses of L-dopa/carbidopa. L-dopa/carbidopa dose (mg) C max (mg/ml) t max (h) AUC (,last) (mg ml - h) 5/2.5.6 ±.37.2 ± ±.54 /.4 ±.56.2 ±.82.4 ±.42 /25.34 ±.82.8 ±.62.4 ±.35 5/37.5. ± ± ±.33 2/5.65 ± ±.44.4 ±.33 25/25.69 ± ± ±.4 Values are means with s.d., n = mg in the mg fixed-combination tablet of L-dopa improved the bioavailability of the latter. These data are in agreement with findings from a previous study [8]. Furthermore, the proportional increase in L-dopa AUC caused by entacapone tended to be somewhat more pronounced with the /25-mg dose. More efficient DDC inhibition at this dose probably explains this observation. The formation of 3-OMD is somewhat greater after the /25 mg dose than after the / mg dose. Consequently, the effects of entacapone are more pronounced after the /25 mg dose. It has been reported that another COMT inhibitor, tolcapone, increases the C max of L-dopa [9, 2, 2]. The data from the present study indicate clearly that simultaneous administration of entacapone decreased rather than increased the peak concentration (C max ) of L-dopa. A similar decrease in the C max of L-dopa has also been observed in PD patients after a day combined treatment with standard-release L-dopa/carbidopa 2/5 mg and entacapone 2 mg, but this did not occur with controlled release of L-dopa/carbidopa at the same dose []. This decrease in C max is clinically beneficial and together with the increased AUC of L-dopa, it will help 22 Blackwell Science Ltd Br J Clin Pharmacol, 54,
8 H. Heikkinen et al. Plasma concentration (mg ml ) OMD DOPAC Placebo Entacapone HVA Time (h) Figure 4 Plasma concentration-time profiles of 3-OMD, DOPAC and HVA after administration of entacapone (2 mg) or placebo with a L-dopa/carbidopa dose of 2/5 mg. Data are presented as means with s.e. mean, n = 4. in delivering more sustained plasma concentrations and lower the risk of dyskinesia at peak dose [22, 23]. The initial absorption of L-dopa was rapid both with and without entacapone and had no lag-phase. It is well established that there may be two or more peaks in the plasma concentration-time curve of L-dopa after a single oral dose [, 2, 6, 7]. In the present study, the highest C max occurred slightly later at some doses when coadministered with entacapone. A similar trend for a delay in the occurrence of L-dopa C max caused by entacapone has been reported in earlier studies performed in PD patients, which describe fluctuations in the time taken for the drug s effects to wear off, but no prolongation in the time for clinical response to the drug [, 24]. Thus, as the initial absorption phase of L-dopa was rapid both with and without entacapone and entacapone did not essentially change the pattern of L-Dopa absorption, the slight delay in the occurrence of L-dopa C max with some L-dopa doses can be considered clinically insignificant. Entacapone clearly affected the plasma concentrations of 3-OMD, DOPAC, and HVA. These changes were most evident during the first 3 5 h after drug administration i.e. during the period when COMT activity was most inhibited by entacapone [4]. Although entacapone primarily inhibits the peripheral degradation of L-dopa to 3-OMD, it also inhibits the metabolism of DOPAC to HVA as a second step in the metabolism of L-dopa [6]. Like L-dopa, carbidopa also exhibits substantial variability in its pharmacokinetics [25, 26]. Although the mean AUC of carbidopa in the presence of entacapone tended to increase at the three highest L-dopa doses, this was not statistically significant. The bioavailability of carbidopa, which also is a substrate for COMT in vitro [27], should theoretically be increased by entacapone, a COMT inhibitor. There was no major difference in the relative bioavailability of entacapone at any of the L-dopa/carbidopa doses. At the two highest doses the absorption phase of entacapone was somewhat prolonged. It has been speculated that entacapone can decrease the rate of stomach emptying [28]. If so, a similar delay in absorption should have occurred at all six L-dopa/carbidopa doses. Despite this observed variability in the absorption rate of entacapone, the changes in L-dopa pharmacokinetics and its metabolism to 3-OMD were comparable at all doses. Consequently, we believe that the apparent delay in the absorption of entacapone observed in this study at the two highest doses of L-dopa/carbidopa most likely reflects the variability in the pharmacokinetics of entacapone, but has no consequence for the clinical effects of entacapone. Our data suggest that entacapone increases the bioavailability of L-dopa at least partly through inhibition of COMT activity, in the upper part of the small intestine, which is known to be rich in the enzyme [29, 3]. Entacapone was well tolerated at all L-dopa/carbidopa doses. There was no difference in the occurrence of adverse events at any dose of L-dopa/carbidopa whether administered with or without entacapone. Headache and nausea were the most common adverse events during both entacapone and placebo periods. Nausea, a known adverse effect of L-dopa, was more common at the higher doses of L-dopa as expected. In conclusion, our data support the regimen of administering entacapone at a dose of 2 mg irrespective of the dose of L-dopa/carbidopa Blackwell Science Ltd Br J Clin Pharmacol, 54,
9 Entacapone increases concentrations of L-dopa References Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 984; 7: Cedarbaum JM. Clinical pharmacokinetics of antiparkinsonian drugs. Clin Pharmacokinet 987; 3: Dingemanse J, Kleinbloesem CH, Zurcher G, et al. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol 997; 44: Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-o-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 994; 46: Heikkinen H, Saraheimo M, Antila S, et al. Pharmacokinetics of entacapone, a peripherally acting catechol-omethyltransferase inhibitor, in man. A study using a stable isotope technique. Eur J Clin Pharmacol 2; 56: Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson s disease. Drugs 2; 59: Rinne UK, Larsen JP, Siden Å, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group Neurol 998; 5: Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson s disease patients. Ann Neurol 997; 42: Myllylä VV, Kultalahti E-R, Haapaniemi H, et al. The Filomen Study Group. Twelve-month safety of entacapone in patients with Parkinson s disease. Eur J Neurol 2; 8: Waters C. Practical issues with COMT inhibitors in Parkinson s disease. Neurology 2; 55: Kaakkola S, Teräväinen H, Ahtila S, et al. Entacapone in combination with standard or controlled-release levodopa/ carbidopa. a clinical and pharmacokinetic study in patients with Parkinson s disease. Eur J Neurol 995; 2: Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psych 996; 6: Heikkinen H, Nutt JG, LeWitt PA, et al. The effects of different repeated doses of entacapone on the pharmacokinetics of L-dopa and on the clinical response to L-dopa in Parkinson s disease. Clin Neuropharmacol 2; 24: Wikberg T. Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal 99; 9: Karlsson M, Wikberg T. Liquid chromatographic determination of a new catechol-o-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J Pharm Biomed Anal 992; : Wade D, Mearrick PT, Birkett DJ, Morris J. Variability of L-dopa absorption in man. Aust NZ J Med 974; 4: Robertson DRC, George CF. Drug therapy for Parkinson s disease in the elderly. Br Med Bull 99; 46: Kaakkola S, Männistö PT, Nissinen E, et al. The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand 985; 72: Jorga K, Fotteler B, Schmitt M, et al. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol 997; 38: Jorga K, Fotteler B, Sedek G, et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/ carbidopa formulation. J Neurol 998; 245: Muller T, Woitalla D, Schulz D, et al. Tolcapone increases maximum concentration of levodopa. J Neural Transm 2; 7: Mouradian M, Heuser JE, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson s disease. Ann Neurol 989; 25: Pearce R, Heikkilä M, Linden I-B, Jenner P. L-dopa induces dyskinesia in normal monkeys. behavioural and pharmacokinetic observations. Psychopharmacology 2; 56: Ruottinen HM, Rinne UK. Effect of one month s treatment with peripherally acting catechol-o-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 996; 9: Vickers S, Stuart EK, Bianchine JR, et al. Metabolism of carbidopa (L-(-) -alfa-hydrazino-3, 4, dihydroxy alfa methylhydrocinnamic acid monohydrate), an aromatic amino acid decarboxylase inhibitor, in the rat, dog, rhesus monkey, and man. Drug Metab Dispos 974; 2: Durso R, Evans JE, Josephs E, et al. Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol 2; 4: Hagan RM, Raxworthy MJ, Gulliver PA. Benserazide and carbidopa as substrates of catechol-o-methyltransferase: new mechanism of action in Parkinson s disease. Biochem Pharmacol 98; 29: Keränen T, Gordin A, Harjola V-P, et al. The effect of catechol-o-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 993; 6: Sharpless NS, Tyce GM, Owen CAJ. Effect of chronic administration of L-dopa on catechol-o-methyltransferase in rat tissues. Life Sci 973; 2: Nissinen E, Tuominen R, Perhoniemi V, Kaakkola S. Catechol-O-methyltransferase activity in human and rat small intestine. Life Sci 988; 42: Blackwell Science Ltd Br J Clin Pharmacol, 54,
The catechol-o-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson s disease
J Neurol Neurosurg Psychiatry 2;68:589 594 589 Department of Neurology, Imperial College, School of Medicine, Hammersmith Hospital, London, UK P Piccini D J Brooks N Pavese Research Centre, Orion Pharma,
More informationEfficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson s disease patients with wearing-off
J Neural Transm (2015) 122:1709 1714 DOI 10.1007/s00702-015-1449-6 NEUROLOGY AND PRECLINICAL NEUROLOGICAL STUDIES - ORIGINAL ARTICLE Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide
More informationrelated fluctuations
363journal of Neurology, Neurosurgery, and Psychiatry 1996j6:36-4 Department of Neurology, University of Turku, Turku, Finland H M Ruottinen U K Rinne Correspondence to: Dr H M Ruottinen, Department of
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationThe effects of the COMT inhibitor entacapone on
Br J clin Pharmac 1993; 36: 451-456 The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise S. SUNDBERG', M. SCHEININ2, A. ILLI', J. AKKILA',
More informationResearch and Development Orion Research Centre Orion Pharma
1 Research and Development Orion Research Centre Orion Pharma Division of Pharmacology and Toxicology Department of Pharmacy Faculty of Science University of Helsinki (17$&$321($'58*)253$5.,16216',6($6(
More informationThe Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinson s Disease
234 Current Clinical Pharmacology, 2007, 2, 234-243 The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinson s Disease Soo-Peang Khor a and Ann Hsu b,* a Clinical Pharmacokinetics
More informationThe effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers
Br J Clin Pharmacol 1996; 41: 331 337 The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers J. ROBERTS, D. G. WALLER, A. G. RENWICK, N. O
More informationPharmacokinetic pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa / benserazide
Eur J Clin Pharmacol (2003) 59: 603 609 DOI 10.1007/s00228-003-0680-5 PHARMACODYNAMICS Pedro Silveira Æ Manuel Vaz-da-Silva Æ Luis Almeida Joana Maia Æ Amilcar Falcão Æ Ana Loureiro Leonel Torra o Æ Rita
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationIssues in Emerging Health Technologies
Issues in Emerging Health Technologies Issue 12 Dec 2000 Entacapone: Adjunctive Use in Patients with Advanced Parkinson s Disease Summary Based on current evidence, entacapone provides clinically important
More informationThe pharmacokinetics and dose proportionality of cilazapril
Br. J. clin. Pharmac. (1989), 27, 199S-204S The pharmacokinetics and dose proportionality of cilazapril J. MASSARELLA, T. DEFEO, A. LIN, R. LIMJUCO & A. BROWN Departments of Drug Metabolism and Clinical
More informationSponsor: Sanofi Drug substance(s): SAR342434
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationLack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids
Blackwell Science, Ltdxford, UKBJCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Science, 200254riginal Articleseltamivir and antacids lack of kinetic interactionp. Snell et al. Lack of pharmacokinetic
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
SYNOPSIS Issue Date: 27 April 2009 Document No.: EDMS-PSDB-9908562:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Johnson & Johnson Pharmaceutical Research & Development,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationOptimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
EXPERT OPINION Optimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective David J Brooks Division of Neuroscience, Faculty
More informationPHARMACOKINETIC DYNAMIC RELATIONSHIPS Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics
British Journal of Clinical Pharmacology Br J Clin Pharmacol (2017) 83 540 553 540 PHARMACOKINETIC DYNAMIC RELATIONSHIPS Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics Correspondence
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationContinuous dopaminergic stimulation
Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Study Endpoints: Pharmacokinetics:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: 05.16.17 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationPharmacokinetics and Pharmacodynamics of Entacapone and Tolcapone after Acute and Repeated Administration: A Comparative Study in the Rat
0022-3565/03/3042-498 506$7.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 304, No. 2 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 42846/1032585
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationSaliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System
Drugs R D (2015) 15:79 83 DOI 10.1007/s40268-015-0080-1 ORIGINAL RESEARCH ARTICLE Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationSYNOPSIS. Number of subjects: Planned: 22 Randomized: 23 Treated: 23. Evaluated: Pharmacodynamic: 22 Safety: 23 Pharmacokinetics: 22
SYNOPSIS Title of the study: A randomized, cross-over, open, euglycemic clamp study on the relative bioavailability and activity of 0.6 U/kg insulin glargine and 20 µg lixisenatide, given as on-site mix
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPharmacokinetics of ibuprofen in man. I. Free and total
Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships Ibuprofen kinetics were studied in 15 subjects after four oral doses. Plasma levels of both total and free ibuprofen were
More informationPublic Assessment Report Scientific discussion. Levodopa/Carbidopa/Entacapone Mylan (levodopa, carbidopa, entacapone) SE/H/1548/01-06/DC
Public Assessment Report Scientific discussion Levodopa/Carbidopa/Entacapone Mylan (levodopa, carbidopa, entacapone) SE/H/1548/01-06/DC This module reflects the scientific discussion for the approval of
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Comtan. This scientific discussion has been updated until 1 January 2004. For information on changes after
More informationParkinsonism and Related Disorders
Parkinsonism and Related Disorders 20 (2014) 1335e1340 Contents lists available at ScienceDirect Parkinsonism and Related Disorders journal homepage: www.elsevier.com/locate/parkreldis Comparison of with
More informationPh D. Synopsis 4. WORK PLAN AND METHODOLOGY
4. WORK PLAN AND METHODOLOGY WORK PLAN FOR BIOEQUIVALENCE STUDY OF TOPIRAMATE 1. Literature Review 2. Fasting Bioequivalence Study Clinical Phase Preparation of Clinical study Protocol Recruitment of Volunteers
More informationBioavailability and Related Pharmacokinetics in Man of Orally Administered L-5-Hydroxytryptophan in Steady State
Acra pharmacol. et roxicol. 1980, 46, 257-262. From the University Department of Neurology, the Research Laboratory for etabolic Disorders of the University Department of Clinical Chemistry, Aarhus Kornrnunehospital,
More informationPublic Assessment Report. Scientific discussion. Ropinirol Actavis. Ropinirole hydrochloride DK/H/1212/ /DC
Public Assessment Report Scientific discussion Ropinirol Actavis Ropinirole hydrochloride DK/H/1212/001-007/DC This module reflects the scientific discussion for the approval of Ropinirole film-coated
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Bioavailability is a measurement of the rate and extent of drug that reaches the systemic circulation from a drug product or a dosage form. There are two different types
More informationEffect of Septilin A Herbal Preparation on Pharmacokinetics of Carbamazepine in Rabbits
[Indian Journal of Physiology and Pharmacology (1998): (42), 4, 527] Effect of Septilin A Herbal Preparation on Pharmacokinetics of Carbamazepine in Rabbits Garg, S.K., Afm. S. Islam and Naresh Kumar Department
More informationDifferent effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin K. T. Kivistö, T. Kantola & P. J. Neuvonen Department of Clinical Pharmacology, University of Helsinki and Helsinki
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationTCP Transl Clin Pharmacol
TCP 2015;23(1):26-30 http://dx.doi.org/10.12793/tcp.2015.23.1.26 Bioequivalence study of Donepezil hydrochloride in healthy Korean volunteers ORIGINAL ARTICLE Yewon Choi 1, Su-jin Rhee 1, In-Jin Jang 1,
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationA Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate
Vol. 26 No. 2 August 2003 Journal of Pain and Symptom Management 743 Original Article A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl
More informationEuropean Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations
July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: DUODOPA Intestinal Gel Name of Active Ingredient: Levodopa-carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationResults. Subject Disposition and Demographics Of 37 enrolled subjects, 23 (62.2%) completed the study
Poster 5-20 Effect of Gastric ph on the Bioavailability of in Healthy Subjects James Longstreth, PhD, Marijke H. Adams, PharmD, PhD, 2 Vasi Sperry, PhD, 3 Dan Kajdasz, PhD, 3 Carol R. Reed, MD 3 Longstreth
More informationPublic Assessment Report. Scientific discussion. Metoprololsuccinat Actavis. Prolonged release tablets 25 mg, 50 mg, 100 mg and 200 mg
Public Assessment Report Scientific discussion Metoprololsuccinat Actavis Prolonged release tablets 25 mg, 50 mg, 100 mg and 200 mg Metoprolol succinate This module reflects the scientific discussion for
More informationA double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance
Journal ofneurology, Neurosurgery, and Psychiatry 1989;52:27-212 A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/1 in patients with Parkinson's disease and fluctuating motor
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPreliminary studies of the pharmacokinetics and pharmacodynamics
Br. J. clin. Pharmac. (1987), 23, 137-142 Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers WENDY B. TAYLOR & D. N. BATEMAN Wolfson Unit of Clinical
More informationClinical Trial Results Summary Study EN
Study Number: EN3288-113 Title of Study: A Double-blind, Dose-Ranging, Pilot Study to Evaluate the Safety, Subjective Effects, and Pharmacokinetics of Oxymorphone Hydrochloride in Healthy Subjects Who
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationStudy No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEffect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects
British Journal of Clinical Pharmacology DOI:1.1111/j.1365-21.26.277.x Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects Teijo I. Saari, Kari Laine, Kari
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationFlecainide pharmacokinetics in healthy volunteers: the influence of urinary ph
Br. J. clin. Pharmac. (1985), 20, 333-338 Flecainide pharmacokinetics in healthy volunteers: the influence of urinary ph A. JOHNSTON, S. WARRNGTON' & P. TURNER Department of Clinical Pharmacology, St Bartholomew's
More informationSection 3.F and Section 6 Human Pharmacokinetics and Bioavailability
ZITHROMAX AZITHROMCYIN MYCOBACTERIUM AVIUM INTRACELLULARE TREATMENT NDA SUPPLEMENT Section 3.F and Section 6 Human Pharmacokinetics and Bioavailability Clinical Pharmacology Cross Reference from 3.H.1
More informationClinical Potential of Catechol-O Methyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease
L~ADING ARTICLE ens Drugs 1 (3): 172-179. 1994 1172-7047/94/0003-Q172/S04.(Xl/O Adls International LImited. All rights reserved. Clinical Potential of Catechol-O Methyltransferase (COMT) Inhibitors as
More informationSponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance:
More informationPrincipal Investigator and Study Center: F. Nobuoka, MD Ageo Medical Clinic, 3133 Haraichi, Ageo City, Saitama , Japan
Page 1 APPENDIX 9: ZRHM-PK-05-JP CLINICAL STUDY SUMMARY The study was conducted in Japan from August to November 2013. Principles as defined in International Conference on Harmonization (ICH) Good Clinical
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures, which have been finalised before 1 September 2004. For scientific information on procedures
More informationJieon Lee 1, AnHye Kim 1, Kyung-Sang Yu 1, Jae-Yong Chung 2, Sung-Vin Yim 3 and Bo-Hyung Kim 3 * 1 ORIGINAL ARTICLE
TCP 2015;23(2):49-53 http://dx.doi.org/10.12793/tcp.2015.23.2.49 Pharmacokinetics and bioequivalence of two different 20 mg olmesartan tablets: A randomized, single-dose, two-period crossover study in
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationCONTINUOUS THERAPY BECAUSE LIFE GOESON
CONTINUOUS THERAPY BECAUSE LIFE GOESON Investigating the effectiveness and safety of ND0612, an investigational medicine for patients with advanced Parkinson s Disease New medication limited by Federal
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationDepartment of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai , China
Biomedicine and Biotechnology Volume 2012, Article ID 386230, 4 pages doi:10.1155/2012/386230 Research Article The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Corbilta 50 mg/12.5 mg/200 mg film-coated tablets Corbilta 75 mg/18.75 mg/200 mg film-coated tablets Corbilta 100 mg/25 mg/200
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationEFFECT OF SIMVASTATIN ON THE PHARMACOKINETICS OF SITAGLIPTIN
Effect of EFFECT OF SIMVASTATIN ON THE PHARMACOKINETICS OF SITAGLIPTIN Michael Cerra, Wen-Lin Luo, Susie (Xiujiang) Li, Catherine Matthews, Edward A O'Neill, John A Wagner, S Aubrey Stoch, Matt S Anderson
More informationGuideline for Bioequivalence Studies of Generic Products
English translation of Attachment 1 of Division-tification 0229. 10 of the Pharmaceutical and Food Safety Bureau, dated February 29, 2012 Guideline for Bioequivalence Studies of Generic Products Index
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationPharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole
Aliment Pharmacol Ther 2001; 15: 1563±1569. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole T. ANDERSSON*, K. ROÈ HSS, E.BREDBERG & M. HASSAN-ALIN *Clinical Pharmacology,
More informationSummary of Report Results
Summary of Report Results Abbott Laboratories Name of Study Drug: DUODOPA Intestinal Gel Name of Active Ingredient: Levodopa-Carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page:
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe excretion of zopiclone into breast milk
Br. J. clin. Pharmac. (1990), 30, 267-271 The excretion of zopiclone into breast milk I. MATHESON1, H. A. SANDE2 & J. GAILLOT3 'Department of Pharmacotherapeutics, University of Oslo, Oslo, 2Department
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationProduct: Cinacalcet hydrochloride Clinical Study Report: Page 2 of 670
Page 2 of 670 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C Name of Finished Product: Cinacalcet hydrochloride (Sensipar, Mimpara ) Name of ctive Ingredient: cinacalcet (cinacalcet hydrochloride
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationTHE EFFECTS OF ENTACAPONE ON CARDIORESPIRATORY, AUTONOMIC, AND CLINICAL RESPONSES IN L-DOPA-TREATED PATIENTS WITH PARKINSON S DISEASE
Department of Neurology Helsinki University Central Hospital University of Helsinki, Finland Department of Clinical Physiology and Nuclear Medicine Helsinki University Central Hospital University of Helsinki,
More informationAbsence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin
Blackwell Science, LtdOxford, UKBJCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Science, 200254Original ArticleFondaparinux warfarin interactionr. A. Faaij et al. Absence of an interaction
More informationReport on New Patented Drugs Azilect
Report on New Patented Drugs Azilect Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the Board s Excessive
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationSYNOPSIS. Issue Date: 31 July 2013
SYNOPSIS Issue Date: 31 July 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, LLC YONDELIS Trabectedin (R279741) Protocol No.: ET743-OVC-1003
More informationTCP Transl Clin Pharmacol
TCP 2017;25(1):10-14 http://dx.doi.org/10.12793/tcp.2017.25.1.10 Comparative pharmacokinetic and tolerability evaluation of two simvastatin 20 mg formulations in healthy Korean male volunteers Seol Ju
More informationFDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES
FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES 1 SCOPE In pursuance of section 47 of the Food and Drugs Law 1992, P.N.D.C.L 305B, as amended by Act 523, 1996, these
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationReevaluation of levodopa therapy for the treatment of advanced Parkinson s disease
Parkinsonism and Related Disorders 15, Supplement 1 (2009) S25 S30 www.elsevier.com/locate/parkreldis Reevaluation of levodopa therapy for the treatment of advanced Parkinson s disease Masayuki Yokochi
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationPrincipal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA
SYNOPSIS Issue Date: 06 October 2008 Document No.: EDMS-PSDB-8954363:2. Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name of Active Ingredient(s)
More information